
Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC
Sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in the first line significantly improved PFS vs chemotherapy plus pembrolizumab for patients with PD-L1–positive, advanced or metastatic triple-negative breast cancer (TNBC), based on …